韓波
韓波，男，教授，博士生導(dǎo)師?，F(xiàn)擔(dān)任藥學(xué)院副院長(zhǎng)。2003年畢業(yè)于四川大學(xué)華西藥學(xué)院，獲學(xué)士學(xué)位，2010年畢業(yè)于四川大學(xué)華西藥學(xué)院，獲得藥物化學(xué)博士學(xué)位。2011年破格晉升為副高級(jí)職稱，2015年破格晉升為研究員。2017年受?chē)?guó)家留學(xué)基金委資助以訪問(wèn)學(xué)者赴美國(guó)紐約州立大學(xué)RNA研究所工作。
全國(guó)百篇優(yōu)秀博士論文獎(jiǎng)獲得者，四川省杰出青年基金，教育部科技評(píng)價(jià)與評(píng)審信息系統(tǒng)評(píng)審專家，國(guó)家自然基金通訊評(píng)審專家，四川省科技專家?guī)鞂＜遥?/span>“全國(guó)大學(xué)生藥苑論壇”項(xiàng)目評(píng)審專家。入選四川省學(xué)術(shù)與技術(shù)帶頭人后備人選，四川省中醫(yī)藥管理局學(xué)術(shù)技術(shù)帶頭人后備人選，四川省衛(wèi)生計(jì)生委學(xué)術(shù)技術(shù)帶頭人后備人選，全國(guó)高等中醫(yī)藥院校優(yōu)秀青年，成都市青年聯(lián)合會(huì)常委，成都中醫(yī)藥大學(xué)講席教授；Current Topics in Medicinal Chemistry期刊客座主編；Chemical Reviews、Chemical Communications、Organic Letters、Advanced Synthesis & Catalysis 等十余種國(guó)際知名期刊的同行審稿人。
研究方向?yàn)橹兴幩幮镔|(zhì)的分子網(wǎng)絡(luò)機(jī)制、結(jié)構(gòu)優(yōu)化、多維構(gòu)效關(guān)系和創(chuàng)新藥物研發(fā)。以臨床療效顯著的經(jīng)典中藥藥效成分為研究對(duì)象，融合多層次的藥物結(jié)構(gòu)信息與活性數(shù)據(jù)，系統(tǒng)研究藥效成分“構(gòu)-效-毒”的多維關(guān)系，以此開(kāi)展藥物篩選和創(chuàng)新藥物設(shè)計(jì)開(kāi)發(fā)。
目前主持國(guó)家自然科學(xué)基金3項(xiàng)、十三五“重大新藥創(chuàng)制”科技重大專項(xiàng)、教育部百篇優(yōu)秀博士論文基金、四川省科技重大前沿項(xiàng)目等十余項(xiàng)國(guó)家及省部級(jí)科研項(xiàng)目。獲得“四川省杰出青年基金”、“中國(guó)博士后科學(xué)基金特助”等人才項(xiàng)目資助。以第一作者或通訊作者發(fā)表SCI收錄的論文32篇，其中一作或通訊作者論文中：IF大于10論文3篇，IF大于5論文21篇，學(xué)科領(lǐng)域一區(qū)論文16篇，引用次數(shù)大于100論文2篇，ESI高被引論文1篇。獲得授權(quán)發(fā)明專利13項(xiàng)；出版專著5部；參與制定國(guó)際標(biāo)準(zhǔn)1項(xiàng)。
※主持項(xiàng)目：
1. 2018～2020，中藥防治耐藥菌創(chuàng)新結(jié)構(gòu)藥物研發(fā)，“重大新藥創(chuàng)制”十三五科技重大專項(xiàng)，負(fù)責(zé)人
2. 2018～2021，馬錢(qián)子生物堿誘導(dǎo)程序性細(xì)胞死亡的“效與毒”整合作用機(jī)制以及立體構(gòu)效關(guān)系研究，國(guó)家自然科學(xué)基金面上項(xiàng)目，負(fù)責(zé)人
3. 2016～2019，鉤藤生物堿調(diào)控α-突觸核蛋白依賴的自噬-溶酶體途徑治療帕金森病的作用機(jī)制和構(gòu)效關(guān)系研究，國(guó)家自然科學(xué)基金面上項(xiàng)目，負(fù)責(zé)人
4. 2017～2020，中藥防治耐藥菌新品種篩選及關(guān)鍵創(chuàng)新技術(shù)建立，四川省科技廳研究重大前沿項(xiàng)目，負(fù)責(zé)人
5. 2014～2016，基于“立體構(gòu)效關(guān)系模型”融合生物信息學(xué)研究青黛治療慢粒白血病的藥效物質(zhì)基礎(chǔ)和分子機(jī)制，四川省科技廳杰出青年基金，負(fù)責(zé)人
6. 2014～2016，基于雙催化體系不對(duì)稱合成結(jié)構(gòu)多樣性雜環(huán)骨架，國(guó)家自然科學(xué)基金青年基金，負(fù)責(zé)人
7. 2014～2018，立體選擇性構(gòu)建結(jié)構(gòu)多樣性的藥物骨架，全國(guó)百篇優(yōu)秀博士論文作者專項(xiàng)基金，負(fù)責(zé)人
8. 2013～2014，基于生物信息學(xué)研究大青葉治療CML的藥效物質(zhì)基礎(chǔ)，中國(guó)博士后科學(xué)基金特別資助項(xiàng)目，負(fù)責(zé)人
9. 2012～2014，新型紫杉醇衍生物的設(shè)計(jì)、合成及活性研究，教育部博士學(xué)科點(diǎn)專項(xiàng)科研基金，負(fù)責(zé)人
10. 2017～2021，附子”毒與效“的多維評(píng)價(jià)與整合分析研究，國(guó)家自然科學(xué)基金重點(diǎn)項(xiàng)目，主研人員
[1] Xie, X., Huang, W., Peng, C.*, Han, B.* Organocatalytic Asymmetric Synthesis of Six-Membered Carbocycle-Based Spiro Compounds. Adv. Synth. Catal. 2018, 360(2), 194-228. IF: 5.123
[2] He, X. H., Yang, L., Ji, Y. L., Zhao, Q., Yang, M. C., Huang, W., Peng, C.,* Han, B.* Chemo- and Stereoselective Cross Rauhut-Currier-Type Reaction of Tri-substituted Alkenes Containing Trifluoromethyl Groups. Chem. Eur. J. 2018, 24(8), 1947-1955. IF: 5.160
[3] Zhang, Y., Wang, C., Huang, W., Haruehanroengra, P., Peng, C.*, Sheng, J., Han, B.*, He, G.* Application of organocatalysis in bioorganometallic chemistry: asymmetric synthesis of multifunctionalized spirocyclic pyrazolone–ferrocene hybrids as novel RalA inhibitors. Org. Chem. Front. 2018, 5(14), 2229-2233. IF: 5.455
[4] Wang, X. Y., Wu, F. B., Li, G. Y., Zhang, N., Song, X. R., Zheng, Y., Gong, C. Y., Han, B.*, He, G.* Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy. ActaBiomater. 2018, 74, 414-429. IF: 6.383
[5] Leng, H.-J., Li, Q. Z., Zeng, R., Dai, Q. S., Zhu, H. P., Liu, Y., Huang, W., Han, B.*, Li, J. L.* Asymmetric Construction of Spiropyrazolone Skeletons via Amine-Catalyzed [3+3] Annulation. Adv. Synth. Catal. 2018, 360(2), 229-234. IF: 5.123
[6] Tang, X., Gao, Y. J., Deng, H. Q., Lei, J. J., Liu, S. W., Zhou, L., Shi, Y., Liang, H., Qiao, J., Guo, L., Han, B.*, Cui, H. L.* Catalyst-free [3 + 2] cyclization of dihydroisoquinoline imines and isatin-derived Morita-Baylis-Hillman carbonates via 1,5-electrocyclization: synthesis of tetrahydroisoquinoline-fused spirooxindoles. Org. Biomol. Chem. 2018, 16(18), 3362-3366. IF: 3.423
[7] Cao, C., Huang, W., Zhang, N., Wu, F. B. *, Xu, T., Pan, X. L., Peng, C.*, Han, B.* Narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis. Cell Prolif. 2018, DOI:10.1111/cpr.12518. IF: 4.936
[8] Zhao, Q., Peng, C.*, Huang, H., Liu, S. J., Zhong, Y. J., Huang, W., He, G., Han, B.* Asymmetric synthesis of tetrahydroisoquinoline-fused spirooxindoles as Ras-GTP inhibitors that inhibit colon adenocarcinoma cell proliferation and invasion. Chem. Commun.2018, 54(60), 8359-8362. IF: 6.290
[9] Yang, M. C., Peng, C.*, Huang, H., Yang, L., He, X. H., Huang, W., Cui, H. L., He, G., Han, B.* Organocatalytic Asymmetric Synthesis of Spiro-oxindole Piperidine Derivatives That Reduce Cancer Cell Proliferation by Inhibiting MDM2-p53 Interaction. Org. Lett. 2017, 19(24), 6752-6755. IF: 6.492
[10] Tang, X., Yang, M. C., Ye, C., Liu, L., Zhou, H. L., Jiang, X. J., You, X. L., Han, B.*, Cui, H. L.* Catalyst-free [3 + 2] cyclization of imines and Morita–Baylis–Hillman carbonates: a general route to tetrahydropyrrolo [2,1-a] isoquinolines and dihydropyrrolo [2,1-a] isoquinolines. Org. Chem. Front. 2017, 4(11), 2128-2133. IF: 5.455
[11] Li, X., Huang, W., Liu, Y. Q., Kang, J. W., Xia, D., He, G., Peng, C.*, Han, B.* Control of Activation Mode To Achieve Diastereodivergence in Asymmetric Syntheses of Chiral Spiropiperidinone Derivatives. J. Org. Chem. 2017, 82(1), 397-406. IF: 4.805
[12] Wang, B., Huang, W., Zhou, J., Tang, X., Chen, Y., Peng, C.*, Han, B.* Drug design based on pentaerythritol tetranitrate reductase: synthesis and antibacterial activity of Pogostone derivatives. Org. Biomol. Chem. 2017, 15(31), 6548-6556. IF: 3.423
[13] Yang, L., Huang, W., He, X. H., Yang, M. C., Li, X., He, G., Peng, C.*, Han, B.* Stereoselective Synthesis of Hydropyrano [3,2-b] indolesviaOrganocatalytic Asymmetric Inverse-Electron-Demand Oxa-Diels- Alder Reaction. Adv. Synth. Catal. 2016, 358(18), 2970-2975. IF: 5.123
[14] Leng, H. J., Peng, F., Zingales, S., Huang, W., Wang, B., Zhao, Q., He, G., Peng, C.*, Han, B.* Core-Scaffold-Inspired Asymmetric Synthesis of Polysubstituted Chiral Hexahydropyridazines that Potently Inhibit Breast Cancer Cell Proliferation by Inducing Apoptosis. Chem. Eur. J. 2015, 21(50), 18100-18108. IF: 5.160
[15] Zhou, R., Wu, Q. J., Guo, M. R., Huang, W., He, X. H., Yang, L., Peng, F., He, G., Han, B.* Organocatalytic cascade reaction for the asymmetric synthesis of novel chroman-fused spirooxindoles that potently inhibit cancer cell proliferation. Chem. Commun.2015, 51(66), 13113-13116. IF: 6.290
[16] Han, B., Huang, W., Ren, W., He, G., Wang, J. h., Peng, C.* Asymmetric Synthesis of Cyclohexane-Fused Drug-Like Spirocyclic Scaffolds Containing Six Contiguous Stereogenic CentersviaOrganocatalytic Cascade Reactions. Adv. Synth. Catal. 2015, 357(2-3), 561-568. IF: 5.123
[17] Han, B., Xie, X., Huang, W., Li, X., Yang, L., Peng, C.* Organocatalytic Morita- Baylis-Hillman/Michael/Acetalization Cascade: Procedure-Controlled Diastereodivergence in the Asymmetric Synthesis of Fully Substituted Tetrahydropyrans. Adv. Synth. Catal.2014, 356(17), 3676-3682. IF: 5.123
[18] He, G., Wu, F. B., Huang, W., Zhou, R., Ouyang, L., Han, B.* One-Pot Asymmetric Synthesis of Substituted Tetrahydrofuransviaa Multicatalytic Benzoin/Michael/Acetalization Cascade. Adv. Synth. Catal. 2014, 356(10), 2311-2319. IF: 5.123
[19] Li, X., Yang, L., Peng, C.*, Xie, X., Leng, H. J., Wang, B., Tang, Z. W., He, G., Ouyang, L., Huang, W., Han, B.* Organocatalytic tandem Morita-Baylis-Hillman-Michael reaction for asymmetric synthesis of a drug-like oxa-spirocyclic indanone scaffold. Chem. Commun. 2013, 49(77), 8692-8694. IF: 6.290
[20] Xie, X., Peng, C.*, He, G., Leng, H. J., Wang, B., Huang, W., Han, B.* Asymmetric synthesis of a structurally and stereochemically complex spirooxindole pyran scaffold through an organocatalytic multicomponent cascade reaction. Chem. Commun. 2012, 48(85), 10487-10489. IF: 6.290
[21] Han, B., Xiao, Y. C., Yao, Y., Chen, Y. C.* Lewis acid catalyzed intramolecular direct ene reaction of indoles. Angew. Chem. Int. Ed. 2010, 49(52), 10189-10191. IF: 12.102
[22] Han, B., Xiao, Y. C., Zhao, Q. H., Chen, Y. C.* Asymmetric Michael Addition of γ,γ-Disubstituted α,β-Unsaturated Aldehydes to Nitroolefins via Dienamine Catalysis. Org. Lett. 2009, 11(20), 4660-4663. IF:6.492
[23] Han, B., He, Z. Q., Li, J. L., Li, R., Jiang, K., Liu, T. Y., Chen, Y. C.* Organocatalytic regio- and stereoselective inverse-electron-demand aza-Diels-Alder reaction of α,β-unsaturated aldehydes and N-tosyl-1-aza-1,3-butadienes. Angew. Chem. Int. Ed. 2009, 48(30), 5474-5477. IF: 12.102
[24] Han, B., Li, J. L., Ma, C., Zhang, S. J., Chen, Y. C.* Organocatalytic Asymmetric Inverse-Electron-Demand Aza-Diels-Alder Reaction of N-Sulfonyl-1-aza-1,3-butadienes and Aldehydes. Angew. Chem. Int. Ed. 2008, 47(51), 9971-9974. IF: 12.102
[25] Han, B., Liu, Q. P., Li, R., Tian, X., Xiong, X. F., Deng, J. G., Chen, Y. C.* Discovery of Bifunctional Thiourea/Secondary-Amine Organocatalysts for the Highly Stereoselective Nitro-Mannich Reaction of α-Substituted Nitroacetates. Chem. Eur. J. 2008, 14(27), 8094-8097. IF: 5.160
※授權(quán)專利：
1. 多取代基類型的γ-吡喃并吡咯烷酮化合物及制備方法和用途 ，ZL201610081072.2，發(fā)明專利
2. 巴比妥酸手性環(huán)己烷螺環(huán)化合物及其制備方法與用途，ZL201510036802.2，發(fā)明專利
3. 一種四氫吡喃醇系列手性化合物及其合成方法和用途，ZL201410415790.X，發(fā)明專利
4. 一種化合物晶型，ZL201410415634.3，發(fā)明專利
5. 茚酮內(nèi)鹽衍生物及其晶型和它們的制備方法與用途，ZL201510191363.2，發(fā)明專利
6. 一種1,3-茚滿二酮衍生物及其晶型，ZL201510191738.5，發(fā)明專利
7. 一種化合物的拆分方法，ZL201410415353.8，發(fā)明專利
8. 羅丹寧手性環(huán)己烷螺環(huán)化合物的晶型及其制備方法與用途，ZL201510072781.X，發(fā)明專利
9. 茚滿二酮手性環(huán)己烷螺環(huán)化合物及其制備方法與用途，ZL201510037231.4，發(fā)明專利
10. 羅丹寧手性環(huán)己烷螺環(huán)化合物及其制備方法與用途，ZL201510036832.3，發(fā)明專利
11. 一種呋喃內(nèi)酯環(huán)類衍生物的晶型，ZL201410110978.3，發(fā)明專利
12. 呋喃內(nèi)酯環(huán)類衍生物及其用途，ZL201410110990.4，發(fā)明專利
13. 含季碳手性中心的呋喃內(nèi)酯環(huán)類化合物的合成方法，ZL201410115288.7，發(fā)明專利
※獎(jiǎng)勵(lì)及學(xué)術(shù)任職：
1. 全國(guó)百篇優(yōu)秀博士論文獎(jiǎng)，教育部，國(guó)務(wù)院學(xué)位委員會(huì)，2014
2. 全國(guó)高等中醫(yī)藥院校“優(yōu)秀青年”，全國(guó)高等中醫(yī)藥院校青年研究會(huì)，2016
3. 全國(guó)大學(xué)生“藥苑論壇“創(chuàng)新成果一等獎(jiǎng)，教育部高等學(xué)校藥學(xué)類專業(yè)教學(xué)指導(dǎo)委員會(huì)，2015
4. 四川省學(xué)術(shù)與技術(shù)帶頭人后備人選，2014
5. Curr. Top. Med. Chem. 期刊，客座主編，2016
6. 成都市青年聯(lián)合會(huì)，常委，2016
7. 四川省衛(wèi)生計(jì)生委學(xué)術(shù)技術(shù)帶頭人后備人選，2016
8. 四川省中醫(yī)藥管理局學(xué)術(shù)技術(shù)帶頭人后備人選，2017
9. 世界中醫(yī)藥學(xué)會(huì)聯(lián)合會(huì)“中藥上市后再評(píng)價(jià)專業(yè)委員會(huì)”，常務(wù)理事，2017